Terms: = Liver cancer AND ABL2, ARG, 27, ENSG00000143322, P42684, ABLL, RP11-177A2_3 AND Prognosis
8876 results:
1. Epidemiological, Diagnostic and Therapeutic Aspects of Hepatocellular Carcinoma in Morocco: A Case Series and Review of Literature.
Zouaki I; Aiterrami A; Samlani Z; Oubaha S; Krati K
Gulf J Oncolog; 2024 May; 1(45):75-90. PubMed ID: 38774936
[TBL] [Abstract] [Full Text] [Related]
2. Epigastric Pain and Dysphagia in a 36-Year-Old Man Due to Primary Esophageal Small Cell Carcinoma.
Aijaz P; Niazi MA; Chela HK; Zahid K; Daglilar E
Am J Case Rep; 2024 May; 25():e943392. PubMed ID: 38773743
[TBL] [Abstract] [Full Text] [Related]
3. Predictive nomograms based on gamma-glutamyl transpeptidase to prealbumin ratio for prognosis of hepatocellular carcinoma patients without microvascular invasion.
Ma M; Xie K; Jin T; Xu F
BMC Cancer; 2024 May; 24(1):617. PubMed ID: 38773511
[TBL] [Abstract] [Full Text] [Related]
4. The effect of liver metastases on clinical efficacy of first-line programmed death-1 inhibitor plus chemotherapy in esophageal squamous cell carcinoma: A post hoc analysis of ASTRUM-007 and meta-analysis.
Gao J; Song Y; Kou X; Tan Z; Zhang S; Sun M; Zhou J; Fan M; Zhang M; Song Y; Li S; Yuan Y; Zhuang W; Zhang J; Zhang L; Jiang H; Gu K; Ye H; Ke Y; Qi X; Wang Q; Zhu J; Huang J
Cancer Med; 2024 May; 13(10):e7203. PubMed ID: 38769930
[TBL] [Abstract] [Full Text] [Related]
5. Effect of cytokines on advanced hepatocellular carcinoma prognosis receiving radiotherapy and tislelizumab plus anlotinib: a single-center phase II clinical trial.
Lin YD; Wu GS; Rao MY; Liu YH; Han YW; Zhang J; Zhang JW
Sci Rep; 2024 May; 14(1):11486. PubMed ID: 38769368
[TBL] [Abstract] [Full Text] [Related]
6. A multi-parametric prognostic model based on clinicopathologic features: vessels encapsulating tumor clusters and hepatic plates predict overall survival in hepatocellular carcinoma patients.
Xiong SP; Wang CH; Zhang MF; Yang X; Yun JP; Liu LL
J Transl Med; 2024 May; 22(1):472. PubMed ID: 38762511
[TBL] [Abstract] [Full Text] [Related]
7. cancer survival in sub-Saharan Africa (SURVCAN-3): a population-based study.
Joko-Fru WY; Bardot A; Bukirwa P; Amidou S; N'da G; Woldetsadik E; Chesumbai G; Korir A; Kamaté B; Koon M; Hansen R; Finesse A; Somdyala N; Chokunonga E; Chigonzoh T; Liu B; Kantelhardt EJ; Parkin DM; Soerjomataram I
Lancet Glob Health; 2024 Jun; 12(6):e947-e959. PubMed ID: 38762297
[TBL] [Abstract] [Full Text] [Related]
8. Epstein
Peng L; Peng X; Duan S; Zhang Z
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2024 Feb; 49(2):319-330. PubMed ID: 38755729
[TBL] [Abstract] [Full Text] [Related]
9. Patterns of distant metastasis and survival outcomes in
Liu K; Huang AL; Chen XQ; Wu SG
Front Endocrinol (Lausanne); 2024; 15():1385756. PubMed ID: 38752173
[TBL] [Abstract] [Full Text] [Related]
10. Construction of a prognostic model for extensive-stage small cell lung cancer patients undergoing immune therapy in northernmost China and prediction of treatment efficacy based on response status at different time points.
Dang J; Xu G; Guo G; Zhang H; Shang L
J Cancer Res Clin Oncol; 2024 May; 150(5):255. PubMed ID: 38750370
[TBL] [Abstract] [Full Text] [Related]
11. [Aprospective study of detection and clinical significance of bone marrow tumor cells in small cell lung cancer].
Wang Y; Lu BH; Gao Y; Liu YX; Hu MM; Che NY; Lin HF; Li HX; Zhang HM; Zhang TM
Zhonghua Zhong Liu Za Zhi; 2024 May; 46(5):419-427. PubMed ID: 38742355
[No Abstract] [Full Text] [Related]
12. Early detection and prognosis evaluation for hepatocellular carcinoma by circulating tumour DNA methylation: A multicentre cohort study.
Guo DZ; Huang A; Wang YC; Zhou S; Wang H; Xing XL; Zhang SY; Cheng JW; Xie KH; Yang QC; Ma CC; Li Q; Chen Y; Su ZX; Fan J; Liu R; Liu XL; Zhou J; Yang XR
Clin Transl Med; 2024 May; 14(5):e1652. PubMed ID: 38741204
[TBL] [Abstract] [Full Text] [Related]
13. Development of a machine learning-based model to predict prognosis of alpha-fetoprotein-positive hepatocellular carcinoma.
Dong B; Zhang H; Duan Y; Yao S; Chen Y; Zhang C
J Transl Med; 2024 May; 22(1):455. PubMed ID: 38741163
[TBL] [Abstract] [Full Text] [Related]
14. Identification of vitamin D-related signature for predicting the clinical outcome and immunotherapy response in hepatocellular carcinoma.
Wang T; Han L; Xu J; Guo B
Medicine (Baltimore); 2024 May; 103(19):e37998. PubMed ID: 38728505
[TBL] [Abstract] [Full Text] [Related]
15. IL-2RG as a possible immunotherapeutic target in CRC predicting poor prognosis and regulated by miR-7-5p and miR-26b-5p.
Gharib E; Rejali L; Piroozkhah M; Zonoobi E; Nasrabadi PN; Arabsorkhi Z; Baghdar K; Shams E; Sadeghi A; Kuppen PJK; Salehi Z; Nazemalhosseini-Mojarad E
J Transl Med; 2024 May; 22(1):439. PubMed ID: 38720389
[TBL] [Abstract] [Full Text] [Related]
16. Diacylglycerol kinase alpha is a proliferation marker of intrahepatic cholangiocarcinoma associated with the prognosis.
Shichi S; Sugiyama K; Asahi Y; Shirakawa C; Nakamoto H; Kimura S; Wakizaka K; Aiyama T; Nagatsu A; Orimo T; Kakisaka T; Taketomi A
Cancer Med; 2024 May; 13(9):e7238. PubMed ID: 38716625
[TBL] [Abstract] [Full Text] [Related]
17. Comprehensive Analysis of the Immunosuppressive Function of Regulatory T Cells in Human Hepatocellular Carcinoma Tissues.
Ge J; Chen J; Shen Q; Zheng X; Chen X; Shi L; Chen L; Xu B
Cancer Control; 2024; 31():10732748241251580. PubMed ID: 38712609
[TBL] [Abstract] [Full Text] [Related]
18. The pattern of tumor progression on first-line immune checkpoint inhibitor-based systemic therapy for Chinese advanced hepatocellular carcinoma -CLEAP 004 study.
Yang CX; Pan YX; Ye F; Zhu XD; Xue J; Li X; Yuan ZG; Zhang L; Xu L; Chen YJ; Wang NY; Sun HC; Liu XF;
Front Immunol; 2024; 15():1310239. PubMed ID: 38711515
[TBL] [Abstract] [Full Text] [Related]
19. Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors for advanced hepatocellular carcinoma with macrovascular invasion.
Zhang Y; Zhang H; Xu H; Wang Y; Feng L; Yi F
World J Surg Oncol; 2024 May; 22(1):122. PubMed ID: 38711095
[TBL] [Abstract] [Full Text] [Related]
20. The clinical significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib and PD-1 inhibitors.
Sun W; Yin X; Liu X; Wei J; Yu M; Li W; Ding X; Chen J
Front Immunol; 2024; 15():1380477. PubMed ID: 38698848
[TBL] [Abstract] [Full Text] [Related]
[Next]
